Abstract
Aims: We report about the add-on therapy of the orphan-drug rufinamide (RUF), which is licensed for Lennox-Gastaut-Syndrome in seven patients with difficult-to-treat Doose-Syndrome (=myoclonic-astatic epilepsy, MAE).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
